Académique Documents
Professionnel Documents
Culture Documents
and V Bonicalzi
)
[
6
0
]
D
r
e
w
e
s
e
t
a
l
.
S
C
I
(
2
0
)
V
A
L
D
o
u
b
l
e
-
b
l
i
n
d
,
p
l
a
c
e
b
o
-
c
o
n
t
r
o
l
l
e
d
,
c
r
o
s
s
o
v
e
r
.
V
A
L
i
n
e
f
f
e
c
t
i
v
e
.
N
N
T
:
1
0
(
9
5
%
C
I
:
2
.
7
)
[
6
1
]
P
o
t
t
e
r
e
t
a
l
.
S
C
I
(
2
6
)
F
a
m
p
r
i
d
i
n
e
-
S
R
(
4
-
a
m
i
n
o
p
y
r
i
d
i
n
e
)
R
a
n
d
o
m
i
z
e
d
,
d
o
u
b
l
e
-
b
l
i
n
d
,
d
o
s
e
-
t
i
t
r
a
t
i
o
n
,
c
r
o
s
s
o
v
e
r
.
N
o
s
t
a
t
i
s
t
i
c
a
l
l
y
s
i
g
n
i
f
i
c
a
n
t
b
e
n
e
f
i
t
s
[
6
2
]
C
h
i
o
u
-
T
a
n
e
t
a
l
.
S
C
I
(
1
1
)
M
E
X
R
a
n
d
o
m
i
z
e
d
,
d
o
u
b
l
e
-
b
l
i
n
d
,
p
l
a
c
e
b
o
-
c
o
n
t
r
o
l
l
e
d
,
c
r
o
s
s
o
v
e
r
.
M
E
X
(
a
t
4
5
0
m
g
/
d
a
y
)
i
n
e
f
f
e
c
t
i
v
e
[
6
3
]
H
a
i
n
e
s
a
n
d
G
a
i
n
e
s
C
C
P
(
3
)
K
E
T
O
n
e
r
a
n
d
o
m
i
z
e
d
,
c
o
n
t
r
o
l
l
e
d
.
K
E
T
i
n
e
f
f
e
c
t
i
v
e
d
u
r
i
n
g
t
h
e
u
n
b
l
i
n
d
e
d
r
u
n
-
i
n
p
e
r
i
o
d
.
I
n
t
o
l
e
r
a
b
l
e
s
i
d
e
e
f
f
e
c
t
s
[
6
4
]
F
i
n
n
e
r
u
p
e
t
a
l
.
S
C
I
(
3
0
)
L
A
M
R
a
n
d
o
m
i
z
e
d
,
d
o
u
b
l
e
-
b
l
i
n
d
,
c
r
o
s
s
o
v
e
r
,
p
l
a
c
e
b
o
c
o
n
t
r
o
l
l
e
d
.
L
A
M
m
o
r
e
e
f
f
e
c
t
i
v
e
t
h
a
n
p
l
a
c
e
b
o
o
n
l
y
i
n
s
e
v
e
n
o
f
e
i
g
h
t
p
a
t
i
e
n
t
s
w
i
t
h
i
n
c
o
m
p
l
e
t
e
c
o
r
d
l
e
s
i
o
n
s
[
N
N
T
:
1
2
;
9
5
%
C
I
:
2
]
[
6
5
]
C
a
r
d
e
n
a
s
e
t
a
l
.
S
C
I
(
2
6
,
t
r
a
n
s
i
t
i
o
n
z
o
n
e
p
a
i
n
:
6
)
A
M
Y
R
a
n
d
o
m
i
z
e
d
,
d
o
u
b
l
e
-
b
l
i
n
d
,
p
l
a
c
e
b
o
-
c
o
n
t
r
o
l
l
e
d
.
N
o
s
i
g
n
i
f
i
c
a
n
t
d
i
f
f
e
r
e
n
c
e
s
b
e
t
w
e
e
n
A
M
Y
a
n
d
b
e
n
z
t
r
o
p
i
n
e
b
e
s
i
l
a
t
e
(
a
c
t
i
v
e
p
l
a
c
e
b
o
)
[
6
6
]
T
a
i
e
t
a
l
.
S
C
I
(
7
)
G
A
B
P
r
o
s
p
e
c
t
i
v
e
,
r
a
n
d
o
m
i
z
e
d
,
d
o
u
b
l
e
-
b
l
i
n
d
,
p
l
a
c
e
b
o
-
c
o
n
t
r
o
l
l
e
d
,
c
r
o
s
s
o
v
e
r
.
N
o
n
s
i
g
n
i
f
i
c
a
n
t
t
r
e
n
d
t
o
(
p
a
r
t
i
a
l
)
b
e
n
e
f
i
t
[
6
7
]
R
o
w
b
o
t
h
a
m
e
t
a
l
.
S
C
I
(
5
)
L
e
v
o
r
p
h
a
n
o
l
R
a
n
d
o
m
i
z
e
d
,
d
o
u
b
l
e
-
b
l
i
n
d
,
d
o
s
e
-
r
e
s
p
o
n
s
e
.
M
e
a
n
p
a
i
n
r
e
d
u
c
t
i
o
n
w
i
t
h
h
i
g
h
l
e
v
o
r
p
h
a
n
o
l
d
o
s
a
g
e
i
n
f
o
u
r
p
a
t
i
e
n
t
s
c
o
m
p
l
e
t
i
n
g
t
h
e
s
t
u
d
y
:
3
1
%
.
S
e
e
a
l
s
o
i
n
C
P
o
f
b
r
a
i
n
o
r
i
g
i
n
[
6
8
]
M
o
r
l
e
y
e
t
a
l
.
T
r
a
n
s
v
e
r
s
e
m
y
e
l
i
t
i
s
(
1
)
M
E
T
R
a
n
d
o
m
i
z
e
d
,
d
o
u
b
l
e
-
b
l
i
n
d
,
p
l
a
c
e
b
o
-
c
o
n
t
r
o
l
l
e
d
(
1
9
N
P
p
a
t
i
e
n
t
s
)
.
M
E
T
n
o
t
t
e
s
t
e
d
[
6
9
]
W
a
d
e
e
t
a
l
.
S
C
I
(
4
)
P
l
a
n
t
-
d
e
r
i
v
e
d
C
M
E
C
o
n
s
e
c
u
t
i
v
e
s
e
r
i
e
s
o
f
d
o
u
b
l
e
-
b
l
i
n
d
,
r
a
n
d
o
m
i
z
e
d
,
p
l
a
c
e
b
o
-
c
o
n
t
r
o
l
l
e
d
s
i
n
g
l
e
-
p
a
t
i
e
n
t
c
r
o
s
s
o
v
e
r
t
r
i
a
l
s
.
B
o
t
h
T
H
C
a
n
d
C
B
D
s
i
g
n
i
f
i
c
a
n
t
l
y
s
u
p
e
r
i
o
r
t
o
p
l
a
c
e
b
o
i
n
p
a
i
n
r
e
l
i
e
v
i
n
g
e
f
f
e
c
t
.
S
e
e
a
l
s
o
C
P
o
f
b
r
a
i
n
o
r
i
g
i
n
[
7
0
]
L
e
v
e
n
d
o
g
l
u
e
t
a
l
.
S
C
I
(
2
0
)
G
A
B
P
r
o
s
p
e
c
t
i
v
e
,
r
a
n
d
o
m
i
z
e
d
,
d
o
u
b
l
e
b
l
i
n
d
,
p
l
a
c
e
b
o
-
c
o
n
t
r
o
l
l
e
d
,
c
r
o
s
s
o
v
e
r
.
G
A
B
e
f
f
e
c
t
s
:
i
n
t
e
n
s
i
t
y
a
n
d
f
r
e
q
u
e
n
c
y
o
f
p
a
i
n
a
t
t
a
c
k
s
r
e
d
u
c
t
i
o
n
a
n
d
q
u
a
l
i
t
y
o
f
l
i
f
e
i
m
p
r
o
v
e
m
e
n
t
.
[
7
1
]
C
a
r
l
s
s
o
n
e
t
a
l
.
S
C
I
(
2
)
D
E
X
R
a
n
d
o
m
i
z
e
d
,
d
o
u
b
l
e
-
b
l
i
n
d
,
p
l
a
c
e
b
o
-
c
o
n
t
r
o
l
l
e
d
,
c
r
o
s
s
o
v
e
r
(
1
5
p
a
t
i
e
n
t
s
w
i
t
h
p
o
s
t
-
t
r
a
u
m
a
t
i
c
N
P
)
.
N
o
D
E
X
e
f
f
e
c
t
i
n
o
n
e
p
a
t
i
e
n
t
,
6
9
%
V
A
S
r
e
d
u
c
t
i
o
n
i
n
o
n
e
p
a
t
i
e
n
t
[
7
2
]
S
i
d
d
a
l
e
t
a
l
.
S
C
I
(
1
3
7
)
P
r
e
g
a
b
a
l
i
n
M
u
l
t
i
c
e
n
t
e
r
,
p
a
r
a
l
l
e
l
-
g
r
o
u
p
,
d
o
u
b
l
e
-
b
l
i
n
d
,
r
a
n
d
o
m
i
z
e
d
(
p
r
e
g
a
b
a
l
i
n
7
0
p
a
t
i
e
n
t
s
,
p
l
a
c
e
b
o
6
7
p
a
t
i
e
n
t
s
)
.
M
e
a
n
e
n
d
p
o
i
n
t
p
a
i
n
s
c
o
r
e
l
o
w
e
r
i
n
t
h
e
p
r
e
g
a
b
a
l
i
n
g
r
o
u
p
t
h
a
n
t
h
e
p
l
a
c
e
b
o
g
r
o
u
p
:
p
<
0
.
0
0
1
)
.
P
r
e
g
a
b
a
l
i
n
w
a
s
m
o
d
e
s
t
l
y
e
f
f
e
c
t
i
v
e
i
n
p
a
i
n
r
e
l
i
e
f
,
i
m
p
r
o
v
i
n
g
s
l
e
e
p
,
a
n
x
i
e
t
y
a
n
d
o
v
e
r
a
l
l
p
a
t
i
e
n
t
s
t
a
t
u
s
[
7
3
]
A
M
Y
:
A
m
i
t
r
i
p
t
y
l
i
n
e
;
C
B
D
:
C
a
n
n
a
b
i
n
o
l
;
C
B
Z
:
C
a
r
b
a
m
a
z
e
p
i
n
e
;
C
C
P
:
C
o
r
d
c
e
n
t
r
a
l
p
a
i
n
;
C
I
:
C
o
n
f
i
d
e
n
c
e
i
n
t
e
r
v
a
l
;
C
I
T
:
C
i
t
a
l
o
p
r
a
m
;
C
M
E
:
C
a
n
n
a
b
i
s
-
m
e
d
i
c
i
n
a
l
e
x
t
r
a
c
t
s
;
C
P
:
C
e
n
t
r
a
l
p
a
i
n
;
C
P
S
P
:
P
o
s
t
-
s
t
r
o
k
e
c
e
n
t
r
a
l
p
a
i
n
;
D
E
X
:
D
e
x
t
r
o
m
e
t
h
o
r
p
h
a
n
;
D
R
O
:
D
r
o
n
a
b
i
n
o
l
;
G
A
B
:
G
a
b
a
p
e
n
t
i
n
;
K
E
T
:
K
e
t
a
m
i
n
e
;
L
A
M
:
L
a
m
o
t
r
i
g
i
n
e
;
M
E
T
:
M
e
t
h
a
d
o
n
e
;
M
E
X
:
M
e
x
i
l
e
t
i
n
e
;
M
S
:
M
u
l
t
i
p
l
e
s
c
l
e
r
o
s
i
s
;
N
N
T
:
N
u
m
b
e
r
-
n
e
e
d
e
d
t
o
t
r
e
a
t
;
N
P
:
N
e
u
r
o
p
a
t
h
i
c
p
a
i
n
;
S
C
I
:
S
p
i
n
a
l
c
o
r
d
i
n
j
u
r
y
;
S
R
:
S
u
s
t
a
i
n
e
d
r
e
l
e
a
s
e
;
T
H
C
:
T
e
t
r
a
h
y
d
r
o
c
a
n
n
a
b
i
n
o
l
;
V
A
L
:
V
a
l
p
r
o
a
t
e
.
Ca na ve ro & Bonic a lzi
1490 Expert Rev. Neurotherapeutics7(11), (2007)
C
P
o
f
b
r
a
i
n
o
r
i
g
i
n
L
e
i
j
o
n
a
n
d
B
o
i
v
i
e
C
P
S
P
(
1
5
)
C
B
Z
A
M
Y
R
a
n
d
o
m
i
z
e
d
,
d
o
u
b
l
e
-
b
l
i
n
d
,
c
r
o
s
s
o
v
e
r
,
p
l
a
c
e
b
o
-
c
o
n
t
r
o
l
l
e
d
.
S
t
a
t
i
s
t
i
c
a
l
l
y
s
i
g
n
i
f
i
c
a
n
t
p
a
i
n
r
e
l
i
e
f
f
r
o
m
A
M
Y
(
f
r
o
m
C
B
Z
o
n
l
y
f
r
o
m
3
r
d
w
e
e
k
)
.
N
N
T
C
B
Z
:
3
.
4
(
9
5
%
C
I
:
1
.
7
1
0
5
)
,
N
N
T
A
M
Y
:
1
.
7
(
9
5
%
C
I
:
1
.
1
3
.
0
)
[
7
4
]
M
c
Q
u
a
y
e
t
a
l
.
C
P
S
P
(
9
)
D
E
X
R
a
n
d
o
m
i
z
e
d
,
d
o
u
b
l
e
-
b
l
i
n
d
,
p
l
a
c
e
b
o
-
c
o
n
t
r
o
l
l
e
d
,
c
r
o
s
s
o
v
e
r
.
I
n
t
e
g
r
a
l
n
-
o
f
-
1
d
e
s
i
g
n
.
D
E
X
i
n
e
f
f
e
c
t
i
v
e
[
7
5
]
V
e
s
t
e
r
g
a
a
r
d
e
t
a
l
.
C
P
S
P
(
9
/
4
)
C
I
T
/
P
l
a
c
e
b
o
R
a
n
d
o
m
i
z
e
d
,
d
o
u
b
l
e
-
b
l
i
n
d
,
p
a
r
a
l
l
e
l
,
p
l
a
c
e
b
o
-
c
o
n
t
r
o
l
l
e
d
;
C
I
T
i
n
e
f
f
e
c
t
i
v
e
[
7
6
]
V
e
s
t
e
r
g
a
a
r
d
e
t
a
l
.
C
P
S
P
(
3
0
)
L
A
M
R
a
n
d
o
m
i
z
e
d
,
d
o
u
b
l
e
-
b
l
i
n
d
,
p
l
a
c
e
b
o
-
c
o
n
t
r
o
l
l
e
d
,
c
r
o
s
s
o
v
e
r
.
N
o
s
i
g
n
i
f
i
c
a
n
t
e
f
f
e
c
t
s
a
t
l
o
w
e
r
d
o
s
e
s
.
P
a
i
n
s
c
o
r
e
r
e
d
u
c
t
i
o
n
:
a
p
p
r
o
x
i
m
a
t
e
l
y
3
0
%
(
m
e
a
n
i
n
g
f
u
l
r
e
d
u
c
t
i
o
n
i
n
p
a
t
i
e
n
t
s
o
p
i
n
i
o
n
)
.
N
N
T
L
A
M
:
n
o
t
a
p
p
l
i
c
a
b
l
e
[
7
7
]
H
e
i
s
k
a
n
e
n
e
t
a
l
.
C
P
S
P
(
2
)
D
E
X
M
i
x
e
d
p
o
p
u
l
a
t
i
o
n
o
f
2
0
p
a
t
i
e
n
t
s
w
i
t
h
N
P
.
R
e
s
u
l
t
s
n
o
t
s
p
l
i
t
d
o
w
n
a
c
c
o
r
d
i
n
g
t
o
p
a
i
n
t
y
p
e
[
7
8
]
L
a
m
p
l
e
t
a
l
.
P
r
e
v
e
n
t
i
o
n
o
f
C
P
S
P
(
3
9
)
A
M
Y
e
x
t
e
n
d
e
d
-
r
e
l
e
a
s
e
R
a
n
d
o
m
i
z
e
d
,
d
o
u
b
l
e
-
b
l
i
n
d
,
p
l
a
c
e
b
o
-
c
o
n
t
r
o
l
l
e
d
.
1
-
y
e
a
r
f
o
l
l
o
w
-
u
p
.
N
o
s
t
a
t
i
s
t
i
c
a
l
l
y
s
i
g
n
i
f
i
c
a
n
t
b
e
n
e
f
i
c
i
a
l
e
f
f
e
c
t
f
r
o
m
A
M
Y
[
7
9
]
R
o
w
b
o
t
h
a
m
e
t
a
l
.
C
P
S
P
(
1
0
)
M
S
(
8
)
L
e
v
o
r
p
h
a
n
o
l
R
a
n
d
o
m
i
z
e
d
,
d
o
u
b
l
e
-
b
l
i
n
d
,
d
o
s
e
-
r
e
s
p
o
n
s
e
.
S
e
v
e
n
o
f
t
e
n
p
a
t
i
e
n
t
s
w
i
t
h
C
P
S
P
d
i
d
n
o
t
c
o
m
p
l
e
t
e
t
h
e
s
t
u
d
y
(
r
e
a
s
o
n
s
n
o
t
d
e
s
c
r
i
b
e
d
)
.
M
e
a
n
p
a
i
n
r
e
d
u
c
t
i
o
n
i
n
t
h
r
e
e
C
P
S
P
p
a
t
i
e
n
t
s
c
o
m
p
l
e
t
i
n
g
t
h
e
s
t
u
d
y
:
2
3
%
;
i
n
e
i
g
h
t
M
S
p
a
t
i
e
n
t
s
:
6
3
%
[
6
8
]
M
o
r
l
e
y
e
t
a
l
.
C
P
S
P
(
2
)
M
E
T
R
a
n
d
o
m
i
z
e
d
,
d
o
u
b
l
e
-
b
l
i
n
d
,
p
l
a
c
e
b
o
-
c
o
n
t
r
o
l
l
e
d
(
1
9
N
P
p
a
t
i
e
n
t
s
)
.
A
v
e
r
a
g
e
p
a
i
n
i
n
t
e
n
s
i
t
y
w
i
t
h
M
E
T
2
0
m
g
:
C
P
S
P
1
:
6
6
.
9
(
v
s
p
l
a
c
e
b
o
6
6
.
6
)
,
C
P
S
P
2
:
2
6
.
6
(
v
s
p
l
a
c
e
b
o
4
7
)
[
8
0
]
W
a
d
e
e
t
a
l
.
M
S
(
1
8
)
P
l
a
n
t
-
d
e
r
i
v
e
d
C
M
E
C
o
n
s
e
c
u
t
i
v
e
s
e
r
i
e
s
o
f
d
o
u
b
l
e
-
b
l
i
n
d
,
r
a
n
d
o
m
i
z
e
d
,
p
l
a
c
e
b
o
-
c
o
n
t
r
o
l
l
e
d
s
i
n
g
l
e
-
p
a
t
i
e
n
t
c
r
o
s
s
o
v
e
r
t
r
i
a
l
s
.
B
o
t
h
T
H
C
a
n
d
C
B
D
s
i
g
n
i
f
i
c
a
n
t
l
y
s
u
p
e
r
i
o
r
t
o
p
l
a
c
e
b
o
i
n
p
a
i
n
-
r
e
l
i
e
v
i
n
g
e
f
f
e
c
t
[
7
0
]
S
v
e
n
d
s
e
n
e
t
a
l
.
M
S
(
2
4
)
D
R
O
R
a
n
d
o
m
i
z
e
d
,
d
o
u
b
l
e
-
b
l
i
n
d
,
p
l
a
c
e
b
o
-
c
o
n
t
r
o
l
l
e
d
,
c
r
o
s
s
o
v
e
r
.
M
o
d
e
s
t
D
R
O
a
n
a
l
g
e
s
i
c
e
f
f
e
c
t
.
N
N
T
:
3
.
5
(
9
5
%
C
I
:
1
.
9
2
4
.
8
)
[
8
1
]
N
o
t
c
u
t
t
e
t
a
l
.
M
S
(
1
6
)
C
a
n
n
a
b
i
s
e
x
t
r
a
c
t
R
a
n
d
o
m
i
z
e
d
,
p
l
a
c
e
b
o
c
o
n
t
r
o
l
l
e
d
.
B
e
n
e
f
i
t
a
t
n
o
f
i
x
e
d
d
o
s
e
[
8
2
]
T
a
b
l
e
1
.
P
h
a
r
m
a
c
o
l
o
g
i
c
a
l
t
r
e
a
t
m
e
n
t
o
f
c
e
n
t
r
a
l
p
a
i
n
:
o
r
a
l
d
r
u
g
s
(
c
o
n
t
.
)
.
A
u
t
h
o
r
(
s
)
P
a
i
n
t
y
p
e
(
n
)
D
r
u
g
(
s
)
e
m
p
l
o
y
e
d
S
t
u
d
y
d
e
s
i
g
n
a
n
d
r
e
s
u
l
t
s
R
e
f
.
A
M
Y
:
A
m
i
t
r
i
p
t
y
l
i
n
e
;
C
B
D
:
C
a
n
n
a
b
i
n
o
l
;
C
B
Z
:
C
a
r
b
a
m
a
z
e
p
i
n
e
;
C
C
P
:
C
o
r
d
c
e
n
t
r
a
l
p
a
i
n
;
C
I
:
C
o
n
f
i
d
e
n
c
e
i
n
t
e
r
v
a
l
;
C
I
T
:
C
i
t
a
l
o
p
r
a
m
;
C
M
E
:
C
a
n
n
a
b
i
s
-
m
e
d
i
c
i
n
a
l
e
x
t
r
a
c
t
s
;
C
P
:
C
e
n
t
r
a
l
p
a
i
n
;
C
P
S
P
:
P
o
s
t
-
s
t
r
o
k
e
c
e
n
t
r
a
l
p
a
i
n
;
D
E
X
:
D
e
x
t
r
o
m
e
t
h
o
r
p
h
a
n
;
D
R
O
:
D
r
o
n
a
b
i
n
o
l
;
G
A
B
:
G
a
b
a
p
e
n
t
i
n
;
K
E
T
:
K
e
t
a
m
i
n
e
;
L
A
M
:
L
a
m
o
t
r
i
g
i
n
e
;
M
E
T
:
M
e
t
h
a
d
o
n
e
;
M
E
X
:
M
e
x
i
l
e
t
i
n
e
;
M
S
:
M
u
l
t
i
p
l
e
s
c
l
e
r
o
s
i
s
;
N
N
T
:
N
u
m
b
e
r
-
n
e
e
d
e
d
t
o
t
r
e
a
t
;
N
P
:
N
e
u
r
o
p
a
t
h
i
c
p
a
i
n
;
S
C
I
:
S
p
i
n
a
l
c
o
r
d
i
n
j
u
r
y
;
S
R
:
S
u
s
t
a
i
n
e
d
r
e
l
e
a
s
e
;
T
H
C
:
T
e
t
r
a
h
y
d
r
o
c
a
n
n
a
b
i
n
o
l
;
V
A
L
:
V
a
l
p
r
o
a
t
e
.
Ce ntra l pa in syndrome : e luc ida tion of ge ne sis a nd tre a tme nt
www.future-drugs.com 1491
T
a
b
l
e
2
.
P
h
a
r
m
a
c
o
l
o
g
i
c
a
l
t
r
e
a
t
m
e
n
t
o
f
c
e
n
t
r
a
l
p
a
i
n
:
p
a
r
e
n
t
e
r
a
l
d
r
u
g
s
.
A
u
t
h
o
r
(
s
)
P
a
i
n
t
y
p
e
S
t
u
d
y
r
e
s
u
l
t
s
R
e
f
.
G
A
B
A
e
r
g
i
c
a
g
e
n
t
s
P
r
o
p
o
f
o
l
i
v
.
C
a
n
a
v
e
r
o
e
t
a
l
.
;
C
a
n
a
v
e
r
o
a
n
d
B
o
n
i
c
a
l
z
i
C
P
S
P
,
S
C
I
P
a
i
n
a
n
d
a
l
l
o
d
y
n
i
a
a
b
o
l
i
t
i
o
n
i
n
p
r
o
p
o
f
o
l
-
r
e
s
p
o
n
s
i
v
e
p
a
t
i
e
n
t
s
.
C
o
n
t
i
n
u
o
u
s
(
6
2
4
h
)
i
v
.
i
n
f
u
s
i
o
n
i
n
p
r
o
p
o
f
o
l
-
r
e
s
p
o
n
s
i
v
e
p
a
t
i
e
n
t
s
:
t
e
m
p
o
r
a
r
i
l
y
e
f
f
e
c
t
i
v
e
w
i
t
h
p
o
s
t
-
e
f
f
e
c
t
l
a
s
t
i
n
g
h
o
u
r
s
[
8
3
,
8
4
]
S
o
d
i
u
m
a
m
y
l
a
l
i
v
.
M
a
i
l
i
s
e
t
a
l
.
S
C
I
V
A
S
r
e
d
u
c
t
i
o
n
,
d
r
a
m
a
t
i
c
a
l
l
o
d
y
n
i
a
r
e
d
u
c
t
i
o
n
a
n
d
s
u
b
s
t
a
n
t
i
a
l
h
y
p
e
r
a
l
g
e
s
i
a
r
e
d
u
c
t
i
o
n
[
8
5
]
B
a
c
l
o
f
e
n
i
t
.
H
e
r
m
a
n
e
t
a
l
.
C
o
r
d
C
P
S
i
g
n
i
f
i
c
a
n
t
d
y
s
e
s
t
h
e
t
i
c
p
a
i
n
s
u
p
p
r
e
s
s
i
o
n
(
t
h
e
n
s
p
a
s
m
-
r
e
l
a
t
e
d
p
a
i
n
)
[
8
6
]
M
a
r
g
o
t
-
D
u
c
l
o
t
e
t
a
l
.
S
C
I
>
6
0
%
p
a
i
n
r
e
l
i
e
f
i
n
e
i
g
h
t
o
f
1
4
S
C
I
p
a
t
i
e
n
t
s
(
b
e
t
t
e
r
r
e
s
u
l
t
s
o
n
p
a
r
o
x
y
s
m
a
l
p
a
i
n
)
[
8
7
]
O
p
i
o
i
d
s
M
o
r
p
h
i
n
e
i
v
.
A
r
n
e
r
a
n
d
M
e
y
e
r
s
o
n
C
P
I
n
e
f
f
e
c
t
i
v
e
[
8
8
]
P
o
r
t
e
n
o
y
e
t
a
l
.
C
P
S
o
m
e
b
e
n
e
f
i
t
[
8
9
]
K
u
p
e
r
s
e
t
a
l
.
C
P
S
P
,
S
C
I
P
a
i
n
s
e
n
s
o
r
y
r
a
t
i
n
g
n
o
t
a
f
f
e
c
t
e
d
(
t
r
e
n
d
t
o
w
a
r
d
s
i
n
c
r
e
a
s
i
n
g
)
;
p
a
i
n
a
f
f
e
c
t
r
a
t
i
n
g
s
i
g
n
i
f
i
c
a
n
t
l
y
r
e
d
u
c
e
d
[
9
0
]
A
t
t
a
l
e
t
a
l
.
C
P
N
o
s
i
g
n
i
f
i
c
a
n
t
d
i
f
f
e
r
e
n
c
e
i
n
p
a
i
n
r
e
d
u
c
t
i
o
n
b
e
t
w
e
e
n
m
o
r
p
h
i
n
e
a
n
d
p
l
a
c
e
b
o
.
L
o
n
g
-
l
a
s
t
i
n
g
t
r
e
a
t
m
e
n
t
w
i
t
h
o
r
a
l
m
o
r
p
h
i
n
e
e
f
f
e
c
t
i
v
e
o
n
l
y
i
n
t
h
r
e
e
o
f
1
4
p
a
t
i
e
n
t
s
a
t
1
2
1
8
m
o
n
t
h
s
[
9
1
]
K
a
l
m
a
n
e
t
a
l
.
M
S
E
f
f
e
c
t
i
v
e
i
n
2
9
%
o
f
p
a
t
i
e
n
t
s
,
o
n
l
y
a
t
h
i
g
h
d
o
s
e
s
[
9
2
]
F
e
n
t
a
n
y
l
i
v
.
D
e
l
l
e
m
i
j
n
a
n
d
V
a
n
n
e
s
t
e
C
P
M
i
x
e
d
p
o
p
u
l
a
t
i
o
n
o
f
5
3
N
P
p
a
t
i
e
n
t
s
.
D
i
a
z
e
p
a
m
a
s
a
c
t
i
v
e
p
l
a
c
e
b
o
.
D
i
a
z
e
p
a
m
:
n
o
c
l
i
n
i
c
a
l
l
y
s
i
g
n
i
f
i
c
a
n
t
e
f
f
e
c
t
.
B
e
n
e
f
i
c
i
a
l
e
f
f
e
c
t
o
f
f
e
n
t
a
n
y
l
(
i
n
d
e
p
e
n
d
e
n
t
o
f
t
h
e
t
y
p
e
o
f
N
P
)
[
9
3
]
A
l
f
e
n
t
a
n
i
l
i
v
.
E
i
d
e
e
t
a
l
.
S
C
I
C
o
n
t
i
n
u
o
u
s
a
n
d
e
v
o
k
e
d
p
a
i
n
m
a
r
k
e
d
l
y
r
e
d
u
c
e
d
b
y
a
l
f
e
n
t
a
n
i
l
(
s
e
e
a
l
s
o
k
e
t
a
m
i
n
e
i
v
.
)
[
9
4
]
M
o
r
p
h
i
n
e
i
t
.
c
l
o
n
i
d
i
n
e
i
t
.
S
i
d
d
a
l
l
e
t
a
l
.
S
C
I
P
a
i
n
r
e
l
i
e
f
:
i
t
.
m
o
r
p
h
i
n
e
a
l
o
n
e
=
i
t
.
c
l
o
n
i
d
i
n
e
=
p
l
a
c
e
b
o
.
i
t
.
m
o
r
p
h
i
n
e
+
i
t
.
c
l
o
n
i
d
i
n
e
:
s
i
g
n
i
f
i
c
a
n
t
p
a
i
n
r
e
l
i
e
f
.
N
N
T
(
c
o
m
b
i
n
a
t
i
o
n
)
:
7
.
5
[
9
5
]
O
p
i
o
i
d
s
a
n
t
a
g
o
n
i
s
t
s
N
a
l
o
x
o
n
e
i
v
.
B
a
i
n
t
o
n
e
t
a
l
.
C
P
S
P
I
n
e
f
f
e
c
t
i
v
e
[
9
6
]
C
P
:
C
e
n
t
r
a
l
p
a
i
n
;
C
P
S
P
:
P
o
s
t
-
s
t
r
o
k
e
c
e
n
t
r
a
l
p
a
i
n
;
i
t
.
:
I
n
t
r
a
t
h
e
c
a
l
;
i
v
.
:
I
n
t
r
a
v
e
n
o
u
s
;
M
S
:
M
u
l
t
i
p
l
e
s
c
l
e
r
o
s
i
s
;
N
N
T
:
N
u
m
b
e
r
-
n
e
e
d
e
d
t
o
t
r
e
a
t
;
N
P
:
N
e
u
r
o
p
a
t
h
i
c
p
a
i
n
;
S
C
I
:
S
p
i
n
a
l
c
o
r
d
i
n
j
u
r
y
;
V
A
S
:
V
i
s
u
a
l
a
n
a
l
o
g
u
e
p
a
i
n
s
c
a
l
e
.
Ca na ve ro & Bonic a lzi
1492 Expert Rev. Neurotherapeutics7(11), (2007)
L
o
c
a
l
a
n
e
s
t
h
e
t
i
c
s
L
i
d
o
c
a
i
n
e
i
v
.
A
t
t
a
l
e
t
a
l
.
C
P
S
P
S
C
I
S
i
g
n
i
f
i
c
a
n
t
t
e
m
p
o
r
a
r
y
p
a
i
n
,
b
r
u
s
h
-
i
n
d
u
c
e
d
a
l
l
o
d
y
n
i
a
a
n
d
s
t
a
t
i
c
m
e
c
h
a
n
i
c
a
l
h
y
p
e
r
a
l
g
e
s
i
a
r
e
d
u
c
t
i
o
n
.
L
o
n
g
-
l
a
s
t
i
n
g
p
a
i
n
r
e
l
i
e
f
i
n
t
w
o
p
a
t
i
e
n
t
s
.
S
i
d
e
e
f
f
e
c
t
s
i
n
t
w
o
o
f
t
h
r
e
e
p
a
t
i
e
n
t
s
.
N
N
T
:
5
(
S
C
I
p
a
t
i
e
n
t
s
)
[
9
7
]
K
v
a
r
r
n
s
t
r
o
m
e
t
a
l
.
S
C
I
K
e
t
a
m
i
n
e
v
s
l
i
d
o
c
a
i
n
e
.
N
o
s
i
g
n
i
f
i
c
a
n
t
a
n
a
l
g
e
s
i
c
e
f
f
e
c
t
f
r
o
m
l
i
d
o
c
a
i
n
e
.
F
r
e
q
u
e
n
t
s
i
d
e
e
f
f
e
c
t
s
[
9
8
]
F
i
n
n
e
r
u
p
e
t
a
l
.
S
C
I
S
i
g
n
i
f
i
c
a
n
t
r
e
d
u
c
t
i
o
n
o
f
n
e
u
r
o
p
a
t
h
i
c
a
t
-
l
e
v
e
l
a
n
d
b
e
l
o
w
-
l
e
v
e
l
s
p
o
n
t
a
n
e
o
u
s
p
a
i
n
.
M
e
d
i
a
n
p
a
i
n
r
e
d
u
c
t
i
o
n
:
a
p
p
r
o
x
i
m
a
t
e
l
y
3
5
%
.
N
N
T
(
5
0
%
p
a
i
n
r
e
l
i
e
f
)
:
3
[
9
9
]
L
i
d
o
c
a
i
n
e
i
t
.
L
o
u
b
s
e
r
a
n
d
D
o
n
o
v
a
n
S
C
I
O
v
e
r
a
l
l
e
f
f
e
c
t
:
6
5
%
p
a
i
n
r
e
l
i
e
f
(
m
e
a
n
)
i
n
1
2
o
f
1
6
p
a
t
i
e
n
t
s
.
C
o
r
r
e
l
a
t
i
n
g
w
i
t
h
s
p
i
n
a
l
c
a
n
a
l
o
b
s
t
r
u
c
t
i
o
n
a
n
d
s
e
n
s
o
r
y
b
l
o
c
k
l
e
v
e
l
[
1
0
0
]
N
M
D
A
a
n
t
a
g
o
n
i
s
t
s
K
e
t
a
m
i
n
e
i
v
.
B
a
c
k
o
n
j
a
e
t
a
l
.
C
P
P
a
i
n
r
e
l
i
e
f
l
a
s
t
i
n
g
2
3
h
[
1
0
1
]
E
i
d
e
e
t
a
l
.
S
C
I
C
o
n
t
i
n
u
o
u
s
a
n
d
e
v
o
k
e
d
p
a
i
n
m
a
r
k
e
d
l
y
r
e
d
u
c
e
d
b
y
k
e
t
a
m
i
n
e
(
s
e
e
a
l
s
o
a
l
f
e
n
t
a
n
i
l
)
[
9
4
]
K
v
a
r
r
n
s
t
r
o
m
e
t
a
l
.
S
C
I
K
e
t
a
m
i
n
e
v
s
l
i
d
o
c
a
i
n
e
.
S
i
g
n
i
f
i
c
a
n
t
a
n
a
l
g
e
s
i
c
e
f
f
e
c
t
f
r
o
m
k
e
t
a
m
i
n
e
o
n
l
y
.
F
r
e
q
u
e
n
t
s
i
d
e
e
f
f
e
c
t
s
,
e
s
p
e
c
i
a
l
l
y
w
i
t
h
k
e
t
a
m
i
n
e
.
S
e
e
a
l
s
o
l
i
d
o
c
a
i
n
e
i
v
.
[
9
8
]
O
t
h
e
r
s
4
-
a
m
i
n
o
p
y
r
i
d
i
n
e
i
v
.
H
a
n
s
e
b
o
u
t
e
t
a
l
.
S
C
I
P
a
i
n
r
e
d
u
c
t
i
o
n
i
n
f
i
v
e
o
f
s
i
x
p
a
t
i
e
n
t
s
w
i
t
h
i
n
c
o
m
p
l
e
t
e
S
C
I
,
n
o
e
f
f
e
c
t
i
n
t
w
o
p
a
t
i
e
n
t
s
w
i
t
h
c
o
m
p
l
e
t
e
a
n
d
o
n
e
s
e
v
e
r
e
i
n
c
o
m
p
l
e
t
e
S
C
I
[
1
0
2
]
W
h
o
l
e
-
p
l
a
n
t
c
a
n
n
a
b
i
s
-
b
a
s
e
d
m
e
d
i
c
i
n
e
(
-
9
-
t
e
t
r
a
h
y
d
r
o
c
a
n
n
a
b
i
n
o
l
:
c
a
n
n
a
b
i
d
i
o
l
)
s
p
r
a
y
R
o
g
e
t
a
l
.
M
S
M
e
a
n
c
h
a
n
g
e
i
n
p
a
i
n
i
n
t
e
n
s
i
t
y
(
a
t
w
e
e
k
4
)
:
C
B
M
:
-
2
.
7
,
p
l
a
c
e
b
o
:
-
1
.
4
(
p
=
0
.
0
0
5
)
.
C
o
g
n
i
t
i
v
e
s
i
d
e
e
f
f
e
c
t
s
:
i
m
p
a
i
r
e
d
l
o
n
g
-
t
e
r
m
m
e
m
o
r
y
s
t
o
r
a
g
e
[
1
0
3
]
S
+
k
e
t
a
m
i
n
e
i
o
n
t
o
p
h
o
r
e
s
i
s
V
r
a
n
k
e
n
e
t
a
l
.
C
P
N
o
s
i
g
n
i
f
i
c
a
n
t
d
i
f
f
e
r
e
n
c
e
s
i
n
p
a
i
n
s
c
o
r
e
s
(
V
A
S
)
b
e
t
w
e
e
n
k
e
t
a
m
i
n
e
(
5
0
o
r
7
5
m
g
/
d
a
y
)
a
n
d
p
l
a
c
e
b
o
[
1
0
4
]
T
a
b
l
e
2
.
P
h
a
r
m
a
c
o
l
o
g
i
c
a
l
t
r
e
a
t
m
e
n
t
o
f
c
e
n
t
r
a
l
p
a
i
n
:
p
a
r
e
n
t
e
r
a
l
d
r
u
g
s
(
c
o
n
t
.
)
.
A
u
t
h
o
r
(
s
)
P
a
i
n
t
y
p
e
S
t
u
d
y
r
e
s
u
l
t
s
R
e
f
.
C
P
:
C
e
n
t
r
a
l
p
a
i
n
;
C
P
S
P
:
P
o
s
t
-
s
t
r
o
k
e
c
e
n
t
r
a
l
p
a
i
n
;
i
t
.
:
I
n
t
r
a
t
h
e
c
a
l
;
i
v
.
:
I
n
t
r
a
v
e
n
o
u
s
;
M
S
:
M
u
l
t
i
p
l
e
s
c
l
e
r
o
s
i
s
;
N
N
T
:
N
u
m
b
e
r
-
n
e
e
d
e
d
t
o
t
r
e
a
t
;
N
P
:
N
e
u
r
o
p
a
t
h
i
c
p
a
i
n
;
S
C
I
:
S
p
i
n
a
l
c
o
r
d
i
n
j
u
r
y
;
V
A
S
:
V
i
s
u
a
l
a
n
a
l
o
g
u
e
p
a
i
n
s
c
a
l
e
.
Ce ntra l pa in syndrome : e luc ida tion of ge ne sis a nd tre a tme nt
www.future-drugs.com 1493
drugs that have a proven benefit for brain CP, while both
appear more or less ineffective for CP of cord origin. Although
not submitted to formal studies, mexiletine is a valuable drug,
especially in combination with gabapentin/pregabalin; gabap-
entin/pregabalin by themselves are effective in only some
patients [1]. Many other drugs, including opioids, have been
tried, with most patients not benefiting or only mildly so [47].
Cannabinoids do not seem to have advanced therapy to a
meaningful extent. It should also be recalled how all these
drugs have side effects that limit their use, above all in special
patient populations, for example in the elderly and spinal
injured patients (e.g., the anticholinergic effects of amitriptyl-
ine); some have rare, but major toxicities (e.g., StevensJohn-
son syndrome during lamotrigine assumption). Several of the
newer antiepileptics (e.g., topiramate) have not fulfilled the
promise, and neither have some recent antidepressants (e.g.,
reboxetine and selective serotonin reuptake inhibitors) [1].
Electrical neuromodulation
As far as brain CP is concerned, the technique of choice is
extradural cortical stimulation (ECS) of the primary motor or
sensory cortex contralateral to pain [48]. This is a minimally
invasive neurosurgical technique in which a stimulating paddle
is inserted through two burr holes or a small craniotomy on
the dura overlying the appropriate area that covers the painful
region [49]. More than half of patients derive a pain reduction
greater than 40% at 4 years [49]. No mortality or permanent
morbidity (including the kindling of an epileptic syndrome)
have been reported in hundreds of reported cases ever since its
introduction in 1989 [48]. Both spontaneous and evoked com-
ponents are favourably altered. Patients may be selected for
ECS on the basis of pharmacological dissection with GABA
agonists (propofol and barbiturates) [40,50] and trials of tran-
scranial magnetic stimulation, in which stimuli are applied
from an external source [51]. Deep brain stimulation (DBS), in
which one or two electrodes are inserted into the sensory thala-
mus or mesencephalon (periaqueductal/periventricular gray
areas), has dubious effects and may be burdened with rare
mortality and less rare permanent disabling morbidity (glo-
bally 1.4%) [1,52]. DBS has a long history, having being intro-
duced for the treatment of CP in the 1960s: experience over
the years has not borne out initial results [5355]. Spinal cord
stimulation (SCS), in which a paddle is applied to cord seg-
ments extradurally, plays no role for brain CP. For CP of cord
origin with at least partially preserved lemniscal sensibility,
SCS is the primary technique, but often loses effect within
1 year [1,52]. In failures or cases with complete loss of sensibil-
ity, in which SCS is totally ineffective, the choice rests between
ECS and DBS; unfortunately, not enough patients have
accrued to evaluate ECS, and DBS is often ineffective. Trans-
cutaneous electrical nerve stimulation, although the least inva-
sive of all electrical neuromodulatory procedures, is of scarce
benefit in the vast majority of patients and must be applied
several times a day, hindering activities of daily living. If
elected, it is best added on to oral drug therapy [1,52]. Some
patients have been submitted to electroconvulsive therapy with
mixed results; thisis a technique of last resort in highly refractory
cases[52,56].
Chemical neuromodulation
Several drugs have been infused into the subarachnoid space in
order to control CP. However, no evidence-based recommenda-
tion are possible; only anecdotal evidence exists and the few
controlled studies lack enough power and follow-up. A
GABAergic agent, such as baclofen or midazolam, can be
infused through a chronically implanted pump; this is most
effective in combination with clonidine, an adrenergic agent
[1,52]. Opioidsare only rarely effective and, in the long term, have
major endocrinologic and immunologic toxicity [1]. Ziconotide,
a recently approved drug, appearsto be insignificantly effective
on CP and unsafe [57].
Neuroablation
For many years, since the introduction of stereotactic surgery
at the end of the 1940s, neurosurgical ablative techniques,
such as thalamotomies and mesencephalotomies, have been
offered to distraught patients, but results have not held up over
time in most studies, in particular on spontaneous compo-
nents of CP [1,14]. Furthermore, mortality and permanent mor-
bidity often offset an initially positive result. Cingulotomy has
proven of no benefit on the sensory components of CP [1].
Surgery on the cord, including cordectomies and DREZ
coagulations, may relieve evoked and paroxysmal components
in some patients over the long term, but with unacceptable
morbidity [1,14]. The only ablative technique that makes sense
in light of the discussed pathophysiology is a small stereotactic
lesion deep in the corona radiata/internal capsule in order to
interrupt the descending arm of the corticothalamic loop; this
has been confirmed recently in a patient with post-stroke
central pain totally and immediately relieved by subparietal
leukotomy/capsulotomy [58].
Five - ye a r view
For 115 years, CP has been downplayed or downright ignored
by neurologists, being considered a mere curiosity. Studies over
the past 15 years have overturned the conviction of CP being
rare. Nonetheless, even today most neurologists and pain
therapists across the board, including some who contribute to
the scientific literature, have scarce appreciation of the clinical
features of CP, making misdiagnosis or underdiagnosis the norm
rather than not. Even when a correct diagnosis is made, patients
generally are treated according to tradition more than science.
Thistranslatesinto major suffering on the part of patients.
Recent advances, including the clarification of the genesis of
CP, have not yet reached the pain therapists in a rational way.
This is owing to two major reasons: the first is a lack of a pain
medicine specialty; and the second is an inability of those few
who made the advancements possible to interact sensibly in
divulging these advancements. International organizations,
such as the International Association for the Study of Pain
Ca na ve ro & Bonic a lzi
1494 Expert Rev. Neurotherapeutics7(11), (2007)
(IASP), have not affected the clinical practice in a tangible way.
However, when recent progress will reach a vaster professional
audience, the outlook for these patients will improve. In the
not too distant future, neural repair techniques, such as trans-
plantation of stem or engineered cells, might be able to achieve
neural restoration and pain relief without the dangers of con-
temporary techniques [59]; but what is clear is that we now
have a rational therapy (subparietal leucotomy/capsulotomy)
for patients not responding to drug therapy and electrical
stimulation. The challenge for pain therapists is to apply it.
Informa tion re sourc e s
PainOnline
www.painonline.com
Central Pain Syndrome Information Resource
www.painonline.org
Central Pain Syndrome Alliance (CPSA)
www.centralpain.org
Fina nc ia l & c ompe ting inte re sts disc losure
Theauthorshaveno relevant affiliationsor financial involvement
with any organization or entity with a financial interest in or
financial conflict with thesubject matter or materialsdiscussed in
the manuscript. This includes employment, consultancies, hono-
raria, stock ownership or options, expert testimony, grantsor patents
received or pending, or royalties.
No writing assistancewas utilized in the production of this
manuscript.
Key issues
Central pain (CP) affectsseveral millionsof patientsworldwide.
The main sourcesare brain strokes, spinal injuriesand multiple sclerosis.
The generator of CP isa deranged corticothalamic loop between the sensory cortex and the sensory thalamus.
Amitriptyline, lamotrigine and mexiletine are the first-line drugsfor CP, with a secondary role of gabapentin/pregabalin.
Extradural cortical stimulation isthe most effective neurosurgical technique available for CP.
Stereotactic subparietal leucotomy/capsulotomy isthe surgical technique best poised to relieve CP permanently in all patients.
In the future, neural restoration may achieve a cure without the complicationsof current therapy.
Re fe re nc e s
Papersof special note have been highlighted as:
of interest
of considerable interest
1 Canavero S, Bonicalzi V. Central Pain
Syndrome. Pathophysiology, Diagnosisand
Management. Cambridge University Press,
NY, USA (2007).
This is the ultimate source on the subject.
The definitive cure for central pain is
presented and supported.
2 Edinger L. Giebt escentral entstehende
Schmerzen?Dtsch Z. Nervenheilk 1,
262282 (1891).
The paper which introduced the concept
of central pain.
3 Riddoch G. The clinical featuresof central
pain. Lumleian lecture. Lancet 234,
10931098, 11501156, 12051209
(1938).
4 Dejerine J, Roussy G. Le syndrome
thalamique. Rev. Neurol. 14, 521532
(1906).
5 Head H, HolmesG. Researches
into sensory disturbancesfrom
cerebral lesions. Brain 34, 102254
(1911).
Unsurpassed description of central
pain features.
6 Canavero S, Bonicalzi V, Massa-Micon B.
Central neurogenic pruritus: a literature
review. Acta Neurol. Belg. 97, 244247
(1997).
7 Cassinari V, Pagni CA. Central Pain:
A Neurosurgical Survey. Harvard University
Press, USA (1969).
The book in which the anatomical basis of
central pain was defined.
8 Andersen G, Vestergaard K,
Ingeman-Nielsen M, Jensen TS. Incidence
of central post-stroke pain. Pain 61,
187193 (1995).
9 Bowsher D. Stroke and central post-stroke
pain in an elderly population. J. Pain 2,
258261 (2001).
10 Siddall PJ, Taylor DA, McClelland JM,
Rutkowski SB, CousinsMJ. Pain report and
the relationship of pain to physical factors
in thefirst 6 monthsfollowing spinal cord
injury. Pain 81, 187197 (1999).
11 Solaro C, Brichetto G, Amato MP, and the
PaISM study group. The prevalence of pain
in multiple sclerosis. A multicenter cross-
sectional study. Neurology63, 919921
(2004).
12 GonzalesGR, Tuttle SL, Thaler HT,
Manfredi PL. Central pain in cancer
patients. J. Pain 4, 351354 (2003).
13 Djaldetti R, Shifrin A, Rogowski Z,
Sprecher E, Melamed E, Yarnitsky D.
Quantitative measurement of pain
sensation in patientswith Parkinson
disease. Neurology22(62), 21712175
(2004).
14 Tasker RR. In: Central Pain States(3rd
Edition). Loeser JD (Ed.). Bonicas
management of pain, Lippincott Williams
& Wilkins, PA, USA 433457 (2001).
15 Beric A. Spinal cord damage: injury. In:
Textbook of Pain (4th Edition). Wall PD,
Melzack P (Eds). Churchill-Livingstone,
Edinburgh, UK 915927 (1999).
16 Canavero S, Bonicalzi V. Reversible central
pain. Neurol. Sci. 22, 271273 (2001).
17 Kim LJ, Klopfenstein JD, Zabramski JM,
Sonntag VKH, Spetzler RF. Analysisof
pain resolution after surgical resection of
intramedullary spinal cord cavernous
malformations. Neurosurgery58, 106111
(2006).
18 Schott GD. Delayed onset and resolution
of pain. Some observationsand
implications. Brain 124, 10671076
(2001).
19 Canavero S. Dynamic reverberation: a
unified mechanism of central and phantom
pain. Med. Hypoth. 42, 203207 (1994).
Ce ntra l pa in syndrome : e luc ida tion of ge ne sis a nd tre a tme nt
www.future-drugs.com 1495
Original description of the
corticothalamic reverberation loop at the
basis of central pain.
20 Canavero S, Bonicalzi V, Pagni CA et al.
Propofol analgesia in central pain:
preliminary clinical observations. J. Neurol.
242, 561567 (1995).
21 Sarnthein J, Stern J, Aufenberg C,
Rousson V, Jeanmonod D. Increased EEG
power and slowed dominant frequency in
patientswith neurogenic pain. Brain 129,
5564 (2006).
22 Lenz FA, Dougherty PM. Experimental
and clinical aspects. In: Pain ProcessingIn
TheHuman Thalamus. Steriade M,
JonesEG, McCormick DA (Eds). Elsevier,
The Netherlands617652 (1997).
23 Radhakrishnan V, TsoukatosJ, DavisKD,
Tasker RR, Lozano AM, Dostrovsky JO.
A comparison of the burst activity of lateral
thalamic neuronsin chronic pain and
non-pain patients. Pain 80, 567575
(1999).
The paper that killed the role of bursting
in the genesis of central pain.
24 Farmer S. Neural rhythmsin Parkinsons
disease. Brain 125, 11751176
(2002).
25 Pagni CA Canavero S. Functional thalamic
depression in a case of reversible central
pain due to a spinal intramedullary cyst.
Case report. J. Neurosurg. 83, 163165
(1995).
26 KissZHT, Dostrovsky JO, Tasker RR.
Plasticity in human somatosensory
thalamusasa result of deafferentation.
Stereotact. Funct. Neurosurg. 62, 153163
(1994).
27 Finnerup NB, Johannesen IL,
Fuglsang-Frederiksen A, Bach FW,
Jensen TS. Sensory function in spinal cord
injury patientswith and without central
pain. Brain 126, 5770 (2003).
28 Amano K, Kawamura H, Tanikawa T,
Kawabatake H, Iseki H, Taira T.
Stereotactic mesencephalotomy for pain
relief. A plea for stereotactic surgery.
Stereotact. Funct. Neurosurg. 59, 2532
(1992).
29 Falci S, Best L, BaylesR, Lammertse D,
StarnesC. Dorsal root entry zone
microcoagulation for spinal cord injury-
related central pain: operative
intramedullary electrophysiological
guidance and clinical outcome.
J. Neurosurg. 97, 193200 (2002).
30 Kim JS. Medial medullary infarct
aggravatescentral poststroke pain caused by
previouslateral medullary infarct.
Eur. Neurol. 58, 4143 (2007).
31 Canavero S, Pagni CA, Castellano G et al.
The role of cortex in central pain
syndromes: preliminary resultsof
a long-term technetium-99
hexamethylpropyleneamineoxime single
photon emission computed tomography
study. Neurosurgery32, 185191 (1993).
32 Hirato M, Horikoshi S, Kawashima Y,
Satake K, Shibasaki T, Ohye C. The
possible role of the cerebral cortex adjacent
to the central sulcusfor the genesisof
central (thalamic) pain-a metabolic study.
Acta Neurochir. Suppl. (Wien) 58, 141144
(1993).
33 Canavero S, Bonicalzi V, Castellano G.
Two in one: the genesisof central pain.
Pain 64, 394395 (1996).
34 Ducreux D, Attal N, Parker F,
BouhassiraD. Mechanismsof central
neuropathic pain: a combined
psychophysical and fMRI study in
syringomyelia. Brain 129, 963976 (2006).
35 Kim JH, Greenspan JD, Coghill RC,
Ohara S, Lenz FA. Lesionslimited to the
human thalamic principal somatosensory
nucleus(ventral caudal) are associated with
lossof cold sensationsand central pain.
J. Neurosci. 27, 49955005 (2007).
36 Parrent AG, Lozano AM, Dostrovsky JO,
Tasker RR. Central pain in the absence of
functional sensory thalamus. Stereotact.
Funct. Neurosurg. 59, 914 (1992).
In this paper, the possibility that central
pain is elaborated ipsilaterally to pain is
confirmed in the human patient.
37 Canavero S. Bilateral central pain.
Acta Neurol. Belg. 96, 135136 (1996).
38 Kim JS. Delayed-onset ipsilateral sensory
symptomsin patientswith central
post-stroke pain. Eur. Neurol. 40,
201206 (1998).
39 Kim JS. Aggravation of poststroke sensory
symptomsafter a second stroke on the
opposite side. Eur. Neurol. 42, 200204
(1999).
40 Canavero S, Bonicalzi V. Review article.
The neurochemistry of central pain:
evidence from clinical studies, hypothesis
and therapeutic implications. Pain 74,
109114 (1998).
41 Craig AD. A new version of the thalamic
disinhibition hypothesisof central pain.
Pain Forum7, 114 (1998).
42 JonesEG. TheThalamus(2nd Edition).
Cambridge University Press, NY, USA
(2007).
The ultimate source on thalamic
anatomy and physiology. Featuring,
among others, the debunking of
Craigs ill-conceived theory.
43 Greenspan JD, Ohara S, Sarlani E,
LenzFA. Allodynia in patientswith
post-stroke central pain (CPSP) studied by
statistical quantitative sensory testing
within individuals. Pain 109, 357366
(2004).
44 Schott GD. Nosological entities?
Reflex sympathetic dystrophy. J. Neurol.
Neurosurg. Psychiatr. 71, 291295 (2001).
45 Ochoa JL. Truths, errors, and liesaround
reflex sympathetic dystrophy and
complex regional pain syndrome.
J. Neurol. 246, 875879 (1999).
46 Bonicalzi V, Canavero S. Sympathetic pain
again?Lancet 360, 14261427 (2000).
47 Canavero S, Bonicalzi V. Chronic
neuropathic pain. N. Engl. J. Med. 348,
26882689 (2003).
48 Canavero S, Bonicalzi V. Therapeutic
extradural cortical stimulation for central
and neuropathic pain: a review. J. Pain 18,
4855 (2002).
49 Canavero S, Bonicalzi V. Extradural cortical
stimulation for central pain. In: Operative
Neuromodulation. Neural NetworksSurgery.
SakasDE, Simpson B (Eds). Springer
Verlag, Germany 2736 (2007).
Complete explanation of the most
effective neuromodulation technique
available for central pain.
50 Canavero S, Bonicalzi V. Intravenous
subhypnotic propofol in central pain.
A double-blind, placebo-controlled,
crossover study. Clin. Neuropharmacol.
27, 182186 (2004).
51 Canavero S, Bonicalzi V. Transcranial
magnetic stimulation for central pain.
Curr. Pain HeadacheRep. 9, 8789 (2005).
52 Canavero S, Bonicalzi V. Neuromodulation
for central pain. Expert Rev.
Neurotherapeutics3, 591607 (2003).
53 Nandi D, Aziz T,Carter H, Stein J.
Thalamic field potentialsin chronic central
pain treated by periventricular gray
stimulation a seriesof eight cases.
Pain 101, 97107 (2003).
54 Hamani C, Schwalb JM, Rezai AR,
Dostrovsky JO, DavisKD, Lozano AM.
Deep brain stimulation for chronic
neuropathic pain: long-term outcome
and the incidence of insertional effect.
Pain 125, 188196 (2006).
55 Rasche D, Rinaldi PC, Young RF,
Tronnier VM. Deep brain stimulation for
the treatment of variouschronic pain
syndromes. Neurosurg. Focus21(6), E8
(2006).
56 Canavero S, Bonicalzi V. Electroconvulsive
therapy and pain. Pain 89, 301302
(2001).
Ca na ve ro & Bonic a lzi
1496 Expert Rev. Neurotherapeutics7(11), (2007)
57 Bonicalzi V, Canavero S. Intrathecal
ziconotide for chronic pain. JAMA 292,
16811682 (2004).
58 Koszewski W, Jarosz J, Pernak-De Gast J.
Stereotactic posterior capsulolentiform
deafferentation asan effective treatment in
central post-stroke pain. A new surgical
method for intractable central pain control?
Pain Clinic15, 115123 (2003).
The first case to be relieved of central
pain following subparietal
leucotomy/capsulotomy as predicted
by Canavero.
59 Kondziolka D, Wechsler L, Achim C.
Neural transplantation for stroke.
J. Clin. Neurosci. 9, 225230 (2002).
60 Davidoff G, Guarracini M, Roth E, Sliwa J,
Yarkony G. Trazodone hydrochloride in the
treatment of dysesthetic pain in traumatic
myelopathy: a randomized, double-blind,
placebo-controlled study. Pain 29(2),
151161 (1987).
61 DrewesAM, Andreasen A, Poulsen LH.
Valproate for treatment of chronic central
pain after spinal cord injury. A double-
blind cross-over study. Paraplegia32(8),
565569 (1994).
62 Potter PJ, HayesKC, Segal JL et al.
Randomized double-blind crossover trial
of fampridine-SR (sustained release
4-aminopyridine) in patientswith
incomplete spinal cord injury.
J. Neurotrauma15(10), 837849
(1998).
63 Chiou-Tan FY, Tuel SM, Johnson JC,
Priebe MM, Hirsh DD, Strayer JR.
Effect of mexiletine on spinal cord injury
dysesthetic pain. Am. J. Phys. Med. Rehabil.
75(2), 8487 (1996).
64 HainesDR, GainesSP. N of 1 randomised
controlled trialsof oral ketamine in patients
with chronic pain. Pain 83(2), 283287
(1999).
65 Finnerup NB, Sindrup SH, Bach FW,
Johannesen IL, Jensen TS. Lamotrigine in
spinal cord injury pain: a randomized
controlled trial. Pain 96(3), 375383
(2002).
66 CardenasDD, WarmsCA, Turner JA,
Marshall H, Brooke MM, Loeser JD.
Efficacy of amitriptyline for relief of pain in
spinal cord injury: resultsof a randomized
controlled trial. Pain 96(3), 365373
(2002).
67 Tai Q, Kirshblum S, Chen B, MillisS,
Johnston M, DeLisa JA. Gabapentin
in the treatment of neuropathic pain after
spinal cord injury: a prospective,
randomized, double-blind, crossover trial.
J. Spinal Cord Med. 25(2), 100105
(2002).
68 Rowbotham MC, Twilling L, DaviesPS,
Reisner L, Taylor K, Mohr D. Oral opioid
therapy for chronic peripheral and central
neuropathic pain. N. Engl. J. Med. 348(13),
12231232 (2003).
69 Morley JS, Bridson J, Nash TP, MilesJB,
White S, Makin MK. Low-dose methadone
hasan analgesic effect in neuropathic pain:
a double-blind randomized controlled
crossover trial. Palliat. Med. 17(7),
576587 (2003).
70 Wade DT, Robson P, House H, Makela P,
Aram J. A preliminary controlled study to
determine whether whole-plant cannabis
extractscan improve intractable neurogenic
symptoms. Clin. Rehabil. 17(1), 2129
(2003).
71 Levendoglu F, Ogun CO, Ozerbil O,
Ogun TC, Ugurlu H. Gabapentin isa first
line drug for the treatment of neuropathic
pain in spinal cord injury. Spine29(7),
743751 (2004).
72 Carlsson KC, Hoem NO, Moberg ER,
Mathisen LC. Analgesic effect of
dextromethorphan in neuropathic pain.
Acta Anaesthesiol. Scand. 48(3), 328336
(2004).
73 Siddall PJ, CousinsMJ, Otte A, Griesing T,
ChambersR, Murphy TK. Pregabalin in
central neuropathic pain associated with
spinal cord injury: a placebo-controlled
trial. Neurology67(10), 17921800 (2006).
74 Leijon G, Boivie J. Central post-stroke pain
a controlled trial of amitriptyline and
carbamazepine. Pain 36(1), 2736 (1989).
75 McQuay HJ, Carroll D, Jadad AR et al.
Dextromethorphan for the treatment of
neuropathic pain: a double-blind
randomised controlled crossover trial with
integral n-of-1 design. Pain 59(1), 127133
(1994).
76 Vestergaard K, Andersen G, Jensen TS.
Treatment of central post-stroke pain with a
selective serotonin reuptake inhibitor.
Eur. J. Neurol. 3(Suppl. 5), 169 (1996).
77 Vestergaard K, Andersen G, Gottrup H,
Kristensen BT, Jensen TS. Lamotrigine for
central poststroke pain: a randomized
controlled trial. Neurology56(2), 184190
(2001).
78 Heiskanen T, Hartel B, Dahl ML,
SeppalaT, Kalso E. Analgesic effectsof
dextromethorphan and morphine in
patientswith chronic pain. Pain 96(3),
261267 (2002).
79 Lampl C, Yazdi K, Roper C. Amitriptyline
in the prophylaxisof central poststroke
pain. Preliminary resultsof 39 patients
in a placebo-controlled, long-term study.
Stroke33(12), 30303032 (2002).
80 Morley JS, Bridson J, Nash TP, MilesJB,
WhiteS, Makin MK. Low-dosemethadone
hasan analgesic effect in neuropathic pain: a
double-blind randomized controlled crossover
trial. Palliat. Med. 17(7), 576587 (2003).
81 Svendsen KB, Jensen TS, Bach FW. Does
the cannabinoid dronabinol reduce central
pain in multiple sclerosis?Randomised
double blind placebo controlled crossover
trial. Br. Med. J. 329(7460), 253 (2004).
82 Notcutt W, Price M, Miller R et al. Initial
experienceswith medicinal extractsof
cannabisfor chronic pain: resultsfrom 34
N of 1 studies. Anaesthesia59(5),
440452 (2004).
83 Canavero S, Bonicalzi V, Pagni CA et al.
Propofol analgesia in central pain:
preliminary clinical observations.
J. Neurol. 242, 561567 (1995).
84 Canavero S, Bonicalzi V. Intravenous
subhypnotic propofol in central pain.
A double-blind, placebo-controlled,
crossover study. Clin. Neuropharmacol.
27, 182186 (2004).
85 MailisA, Amani N, Umana M, Basur R,
Roe S. Effect of intravenoussodium amytal
on cutaneoussensory abnormalities,
spontaneouspain and algometric pain
pressure thresholdsin neuropathic pain
patients: a placebo-controlled study. II.
Pain 70, 6981 (1997).
86 Herman RM, DLuzansky SC, Ippolito R.
Intrathecal baclofen suppressescentral pain
in patientswith spinal lesions. A pilot
study. Clin. J. Pain 8, 338345 (1992).
87 Margot-Duclot A, Thiebaut J-B, Simon A,
Baud P, Adrianasolo H, Russel B. Effectsof
intrathecal baclofen in cauda equina and
low spinal cord injury pain. In: 10th World
Congresson Pain, Book of Abstracts. IASP
Press, WA, USA A221P217 (2002).
88 Arnr S, Meyerson BA. Lack of analgesic
effect of opioidson neuropathic and
idiopathic formsof pain. Pain 33, 1123
(1988).
89 Portenoy RK, Foley KM, Inturrisi CE.
The nature of opioid responsivenessand its
implicationsfor neuropathic pain: new
hypothesesderived from studiesof opioid
infusions. Pain 43, 273286 (1990).
90 KupersRC, KoningsH, Adriaensen H,
GybelsJM. Morphine differentially affects
the sensory and affective pain ratingsin
neurogenic and idiopathic formsof pain.
Pain 47(1), 512 (1991).
91 Attal N, Guirimand F, Brasseur L, Gaude V,
Chauvin M, Bouhassira D. Effectsof IV
morphine in central pain. A randomized
placebo-controlled study. Neurology58,
554563 (2002).
Ce ntra l pa in syndrome : e luc ida tion of ge ne sis a nd tre a tme nt
www.future-drugs.com 1497
92 Kalman S, Osterberg A, Sorensen J,
BoivieJ, Bertler A. Morphine
responsivenessin a group of well-defined
multiple sclerosispatients: a study with
iv. morphine. Eur. J. Pain 6, 6980
(2002).
93 Dellemijn PL, Vanneste JA. Randomised
double-blind active-placebo-controlled
crossover trial of intravenousfentanyl in
neuropathic pain. Lancet 349, 753758
(1997).
94 Eide PK, Stubhaug A, Stenehjem AE.
Central dysesthesia pain after traumatic
spinal cord injury isdependent on
N-methyl-D-aspartate receptor
activation. Neurosurgery37, 10801087
(1995).
95 Siddall PJ, Molloy AR, Walker S,
Mather LE, Rutkowski SB, CousinsMJ.
The efficacy of intrathecal morphine and
clonidine in the treatment of pain after
spinal cord injury. Anesth. Analg.
91, 14931498 (2000).
96 Bainton T, Fox M, Bowsher D, WellsC.
A double-blind trial of naloxone in central
post-stroke pain. Pain 48, 159162
(1992).
97 Attal N, Gaude V, Brasseur L et al.
Intravenouslidocaine in central pain.
A double-blind, placebo-controlled,
psychophysical study. Neurology54,
564574 (2000).
98 Kvarnstrom A, Karlsten R, Quiding H,
Gordh T. The analgesic effect of
intravenousketamine and lidocaine on pain
after spinal cord injury. Acta Anaesthesiol.
Scand. 48, 498506 (2004).
99 Finnerup NB, Biering-Sorensen F,
Johannesen IL et al . Intravenouslidocaine
relievesspinal cord injury pain. A
randomized controlled trial. Anesthesiology
102, 10231030 (2005).
100 Loubser PG, Donovan WH. Diagnostic
spinal anaesthesia in chronic spinal
cord injury pain. Paraplegia29, 2536
(1991).
101 Backonja M, Arndt G, Gombar KA,
Check B, Zimmermann M. Response of
chronic neuropathic pain syndromesto
ketamine: a preliminary study. Pain 56,
5157 (1994).
102 Hansebout RR, Blight AR, Fawcett S,
Reddy K. 4-aminopyridine in chronic
spinal cord injury: a controlled,
double-blind, cross-over study in
eight patients. J. Neurotrauma 10, 118
(1993).
103 Rog DJ, Nurmikko TJ, Friede T,
YoungCA. Randomized, controlled trial of
cannabisbased medicine in central pain in
multiple sclerosis. Neurology65, 812819
(2005).
104 Vranken JH, Dijkgraaf MG, KruisMR,
van Dasselaar NT, van der Vegt MH.
Iontophoretic administration of
S
+
-ketamine in patientswith intractable
central pain: a placebo-controlled trial.
Pain 118, 224231 (2005).
Affilia tions
S Canavero, MD
Turin Advanced Neuromodulation Group
(Tang), CsoEinaudi 2, 10128 Torino, Italy
Tel.: +39 34 9471 7819
sercan@inwind.it
V Bonicalzi, MD
Turin Advanced Neuromodulation Group
(Tang), CsoEinaudi 2, 10128 Torino, Italy
vbonica@libero.it